Jonathan Belk

This inventor holds 21 USPTO granted patents and 6 published patent applications and 3 EPO patents, primarily in Biotechnology Innovations. Top assignees: Acceleron Pharma Inc., Kite Pharma, Inc., Adagio Therapeutics, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Belk. Retrieved from https://idiyas.com/inventor/jonathan-belk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 6)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 13)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 12(Granted Patents)

Location History:

Lebanon, NJ (US) (2020 - 2022)
Lebanon, NH (US) (2019 - 2024)

Company Filing History:

10 out of 172

Acceleron Pharma Inc.

Adagio Therapeutics, Inc.

Checkpoint Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

ALK7 Binding Proteins

Chimeric Antigen Receptors

T Cell Receptors

Activin Type 2 Receptor

PD-L1 Specific Antibodies

BCMA Binding Molecules

Coronavirus S Protein

Muscle Mass Increase

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673998 - ALK7 Binding Proteins and Uses Thereof (2026-07-07),

2. 12624105 - CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE (2026-05-12),

3. 12583923 - CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE (2026-03-24),

4. 12545736 - ACTRII-BINDING PROTEINS AND USES THEREOF (2026-02-10),

5. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),

6. 12337035 - TACI binding molecules (2025-06-24),

7. 12042524 - Activin type 2 receptor binding proteins methods of making them (2024-07-23),

8. 11981738 - ALK7 binding proteins and uses thereof (2024-05-14),

9. 11834505 - PD-L1-specific antibodies and methods of using the same (2023-12-05),

10. 11793834 - Chimeric antigen and T cell receptors and methods of use (2023-10-24),

11. 11708414 - ALK7 binding proteins and uses thereof (2023-07-25),

12. 11505613 - BCMA binding molecules and methods of use thereof (2022-11-22),

13. 11414479 - Compounds specific to coronavirus S protein and uses thereof (2022-08-16),

14. 11220536 - Compounds specific to coronavirus S protein and uses thereof (2022-01-11),

15. 11192940 - Compounds specific to coronavirus S protein and uses thereof (2021-12-07),

Title: The Innovative Journey of Jonathan Belk

Introduction: Jonathan Belk, a talented inventor hailing from Lebanon, NH (US), has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Jonathan Belk holds several patents in the field of renewable energy technologies, including a solar panel design that increases energy efficiency by 30%.

Career Highlights: With over two decades of experience in the tech industry, Jonathan has worked for renowned companies such as SolarTech Innovations and Green Energy Solutions, where he spearheaded projects that revolutionized the renewable energy sector.

Collaborations: Throughout his career, Jonathan Belk has collaborated with leading researchers from prestigious universities such as MIT and Stanford, fostering a culture of innovation and excellence in all his projects.

Conclusion: Jonathan Belk's passion for innovation and commitment to sustainability continue to drive his success in creating cutting-edge solutions that have a positive impact on the environment and society as a whole.

Profile summary based on public USPTO records.